Tuhura Biosciences, Inc/nv 8-K filings

TuHURA Biosciences has entered into an agreement with Kineta for exclusive rights to acquire Kineta's KVA12123 anti-VISTA antibody, a novel checkpoint inhibitor, while also securing a $5 million private investment.

Kintara Therapeutics and TuHURA Biosciences provided an update on their merger, clinical advancements, and upcoming milestones, including a Phase 3 trial for TuHURA and continued enrollment in Kintara's REM-001 study.

Kintara Therapeutics successfully held its annual meeting, electing directors, approving executive compensation, and ratifying the appointment of its accounting firm.

Kintara Therapeutics has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, while also progressing with its proposed merger with TuHURA.

TuHURA Biosciences and Kintara Therapeutics announced positive results from a Phase 1b trial of IFx-2.0, a personalized cancer vaccine, and detailed their planned merger.

Kintara Therapeutics reported its third quarter fiscal 2024 financial results, highlighted by a reduced net loss and announced a merger agreement with TuHURA Biosciences.

Kintara Therapeutics has scheduled its 2024 annual meeting for June 20, 2024, and established deadlines for shareholder proposals and director nominations.

Kintara Therapeutics and TuHURA Biosciences are merging to advance their oncology pipelines, with TuHURA's cancer vaccine trial results being presented at the upcoming ASCO meeting.

Kintara Therapeutics and TuHURA Biosciences have agreed to merge, creating a company focused on advancing personalized cancer vaccines and bi-functional antibody drug conjugates.

Kintara Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent $8.1 million capital raise.

Kintara Therapeutics believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement after raising $8.1 million through an at-the-market offering.

Kintara Therapeutics has completed its utilization of its at-the-market facility and ceased using its equity facility, according to a recent filing.

Kintara Therapeutics reported its second quarter fiscal 2024 results, highlighted by a reduced net loss and the initiation of a new clinical trial for its REM-001 therapy, while also announcing a strategic review process.

Kintara Therapeutics has commenced a 15-patient clinical trial for REM-001, a photodynamic therapy, targeting cutaneous metastatic breast cancer.